Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Timber Pharmaceuticals, Inc. (TMBR)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.3985-0.0191 (-4.57%)
At close: 04:00PM EST
0.4055 +0.01 (+1.76%)
After hours: 04:35PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close0.4176
Open0.4100
Bid0.3978 x 3200
Ask0.4024 x 2200
Day's Range0.3930 - 0.4173
52 Week Range0.3930 - 3.6500
Volume2,737,876
Avg. Volume3,011,375
Market Cap25.423M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.2140
Earnings DateNov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TMBR

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Timber Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/03/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    7 months agoArgus Research
View more
  • GlobeNewswire

    Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001

    Call to be held on Monday, November 22nd at 10:00am ET BASKING RIDGE, NJ, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it will host a conference call for investors and shareholders to discuss the positive topline results from its recently completed Phase 2

  • GlobeNewswire

    Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2021 Financial Results

    Positive Top Line Phase 2b Study Data for Lead Asset TMB-001 and Capital Raise of $17.25 Million Announced Subsequent to Quarter End BASKING RIDGE, NJ, Nov. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the third q

  • GlobeNewswire

    Timber Pharmaceuticals Announces Closing of Exercise of Underwriter’s Option to Purchase Additional Common Stock

    Underwritten Public Offering Resulted in Total Gross Proceeds of $17.25 Million Basking Ridge, NJ, Nov. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the underwriter of its previously announced underwritten public offering which closed on November 5, 2021 has ex

Advertisement
Advertisement